$MC

Moelis & Co (MC): Submission of Matters to a Vote of Security Holders

Moelis & Co (MC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K Moelis & Co false 0001596967 0001596967 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported

Original reporting
Published Jun 26, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$MC
Neutral
medium confidence
Mentioned
$MC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MCNeutralLow
01

Why it matters

The disclosure finalizes outcomes for (1) election of seven directors, (2) non-binding advisory approval of named executive officer compensation, and (3) ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending Dec. 31, 2026.

02

Market read

Confirms governance decisions and reduces uncertainty around board/auditor approval, but provides no new financial or strategic information.

03

What to watch

Traders may instead focus on any concurrent 8-K items (not present here) such as executive changes, financing, or litigation—this filing alone is not a fundamental driver.

Relevance 6/10Novelty 2/10Timing: after-hours/filing update following the June 25 annual meeting

Background

Moelis & Co (MC) submitted an SEC Form 8-K under Item 5.07 to report final results of votes at its 2026 Annual Meeting of Stockholders held June 25, 2026.

Company-level read

Ticker impact

$MCNeutralMedium confidence
Context

Moelis & Co filed an 8-K reporting final vote results from its June 25, 2026 annual meeting, including director elections and auditor ratification.

Expected impact

Low likelihood of a sustained price move solely from these vote tallies; any reaction would be limited to governance sentiment.

Evidence & confidence

An 8-K Item 5.07 is procedural (final tabulation) and does not introduce new financial guidance, transactions, or enforcement outcomes.

Market effects

Minimal; governance vote outcomes are company-specific and do not signal sector-wide regulatory or earnings changes.

Minimal; no cross-border transaction or macro linkage is disclosed.

Minimal; the disclosure is limited to corporate governance mechanics.

Counterpoint

If there were unusually close votes (e.g., director or comp opposition), it could hint at shareholder dissatisfaction; however, the filing provides no narrative or thresholds to interpret that as a catalyst.

Key entities

  • Moelis & Co

    Subject of the 8-K; reported final shareholder vote tabulations for board, advisory comp, and auditor ratification.

  • Deloitte & Touche LLP

    Independent registered public accounting firm ratified by stockholders for 2026.

Related articles

$PJTMed

Investment Banking & Brokerage Stocks Q2 In Review: PJT (NYSE:PJT) Vs Peers

Perella Weinberg (PJT) reported flat revenue of $156.5M, beating EPS estimates, with stock up 7.1%. Houlihan Lokey (HLI) saw revenue drop 15.6% to $511M, missing estimates, with stock down 8%. Goldman Sachs (GS) reported $20.34B revenue, up 39.5%, beating estimates, but stock down 4%. Moelis (MC) reported $409.4M revenue, up 12%, beating estimates, with stock up 2.5%.

$MCMed

Moelis & Co (MC): Results of Operations and Financial Condition

Moelis & Co (MC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Moelis & Company Reports Second Quarter and First Half 2026 Financial Results; Declares Regular Quarterly Dividend of $0.65 Per Share • Record second quarter revenues of $409.4 million, up 12% from the prior year period • Record first half revenues of $729.2 million,

$HALOMedAI 9/10

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

Halozyme Therapeutics (HALO) priced a $1.3B upsized offering of 1.50% convertible senior notes due 2033, with a 13-day option for additional $200M. Notes have an initial conversion price of $139.84, a 27.5% premium over the closing price. Proceeds (~$1.275B) will fund capped call transactions, repurchase existing notes, and general corporate purposes. The company expects to close the offering on September 22, 2026.

$CTVAMed

Corteva Fires Back as States Move to Block Corporate Split on Oct. 1

Corteva is defending its planned split into two companies, Corteva and Vylor, against a legal challenge from 21 states. The states argue the split could hinder PFAS liability claims, but Corteva denies wrongdoing and asserts the separation is strategic. Corteva plans to keep its headquarters in Indianapolis, while Vylor will be based in Iowa. The court will decide if the split can proceed as scheduled on Oct. 1.

HighAI 9/10

CoreWeave $3B Convertible Debt Plan

CoreWeave plans a $3B convertible debt sale, with an option for an additional $500M. The company also authorized an at-the-market share sale of up to 35M shares. Proceeds will fund AI compute infrastructure and offset dilution. In Q3, CoreWeave signed deals for compute capacity at an annualized rate of $40M per megawatt, increasing its contracted power capacity to 4.2 gigawatts.